09 April 2013
Karus Therapeutics appoints Scientific Advisory Board and announces move to new Oxford facilities
Oxford, UK, 9 April 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development. The appointment of Karus’s SAB reflects the Company’s recent expansion and move to fully-integrated research and office facilities near Oxford.
Last month, Karus relocated all its operations to new headquarters at Milton Park, Oxfordshire. The move provides the Company with over 400 sqm of chemistry and biology laboratories, integrated with a corporate headquarters in a world leading biotechnology cluster.
The newly appointed SAB will support the Company’s continued R&D progress and comprises leading R&D professionals from academia and the pharma industry. The SAB will operate under the direction of Karus’s Chief Scientific Officer, Dr Stephen Shuttleworth and members include:
Commenting on the formation of the SAB, Dr Simon Kerry, Chief Executive of Karus, said: “We are very pleased to have attracted such a strong team to our scientific advisory board: they bring breadth and depth of knowledge to Karus, and we look forward to benefitting from their insight and guidance throughout our R&D programmes.
“Our new location in Oxfordshire is essential for Karus to grow: with a high quality team, our network of key opinion leaders and a supportive investor base, we are well positioned to advance our proprietary PI3K and HDAC6 inhibitor programmes into the clinic” he said.